Zapatka M

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.

Tausch E, Ljungström V, Agathangelidis A, ..., Rosenquist R, Stilgenbauer S

Blood 139 (22) 3340-3344 [2022-06-02; online 2022-04-05]

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Herbst SA, Vesterlund M, Helmboldt AJ, ..., Lehtiö J, Dietrich S

- - (-) - [2022-03-04; online 2022-03-04]